You just read:

Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome

News provided by

Lexicon Pharmaceuticals, Inc.

Aug 09, 2011, 06:00 ET